Converting Levetiracetam (Keppra) 750 mg IV to Oral
Switch directly to levetiracetam 750 mg oral twice daily, maintaining the same total daily dose and dosing frequency as the IV regimen. 1
Direct 1:1 Conversion
The conversion from IV to oral levetiracetam is straightforward because both formulations are bioequivalent:
- Oral bioavailability is >95% 1, 2
- No dose adjustment is needed when switching between routes 1
- The same total daily dose and frequency should be maintained 1
For a patient receiving 750 mg IV twice daily (1500 mg total daily dose), simply switch to 750 mg oral twice daily.
Pharmacokinetic Equivalence
The IV and oral formulations produce equivalent systemic exposure:
- Bioequivalence is established with geometric mean IV/oral ratios of 92.2% for AUC and 103.7% for Cmax 2
- Peak concentrations occur at 1.3 hours after oral administration 3
- Steady-state is achieved within 24-48 hours with either formulation 1, 2
- Food slows absorption rate but does not affect total absorption 3
Practical Considerations
Timing of switch: The transition can occur at any scheduled dose time. Simply give the next scheduled dose orally instead of IV.
Formulation options: If the patient has difficulty swallowing tablets, a 10% oral solution is available and bioequivalent to tablets 4. For 750 mg, administer 7.5 mL of the oral solution.
Duration of IV therapy: The FDA label notes there is no clinical study experience with IV levetiracetam administration for periods longer than 4 days 1. The IV formulation is intended as a temporary alternative when oral administration is not feasible 1, 5.
Important Caveats
Renal impairment: If creatinine clearance is <80 mL/min/1.73m², dose adjustments are required for both IV and oral formulations 1. The conversion ratio remains 1:1, but the total dose may need reduction based on renal function.
Tolerability: The adverse effect profile is identical between formulations 1. Common side effects include somnolence (15%), asthenia (15%), dizziness (9%), and headache (14%) 1.